OrbiMed Advisors UNH Position
Exited5-Fund ConvergenceOrbiMed Advisors exited their position in UNITEDHEALTH GROUP INC (UNH) in Q3 2025, after holding the stock for 11 quarters.
The position was first reported in Q1 2023 and has been tracked across 11 quarterly 13F filings.
UNH is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
About UNITEDHEALTH GROUP INC
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage and well-being services to individuals age 50 and older addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance and health care programs; health and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.
Full company profile →Short Interest
1.9%
2.0 days to cover
OrbiMed Advisors UNH Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q3 2025 | Exited | 0 | -336,300 | $0 |
| Q2 2025 | Increased | 336,300 | +135,100 | $104.9M |
| Q1 2025 | Increased | 201,200 | +70,300 | $105.4M |
| Q4 2024 | Decreased | 130,900 | -48,100 | $66.2M |
| Q3 2024 | Increased | 179,000 | +67,000 | $104.7M |
| Q2 2024 | Increased | 112,000 | +42,000 | $57.0M |
| Q1 2024 | Held | 70,000 | — | $34.6M |
| Q4 2023 | Held | 70,000 | — | $36.9M |
| Q3 2023 | Decreased | 70,000 | -174,000 | $35.3M |
| Q2 2023 | Decreased | 244,000 | -32,000 | $117.3M |
| Q1 2023 | New | 276,000 | +276,000 | $130.4M |
Frequently Asked Questions
Does OrbiMed Advisors own UNH?
No. OrbiMed Advisors exited their position in UNITEDHEALTH GROUP INC (UNH) in Q3 2025. They previously held the stock for 11 quarters.
How many hedge funds own UNH?
5 specialist biotech hedge funds currently hold UNH, including Rock Springs Capital, Casdin Capital, Tang Capital Management and 2 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy UNH?
OrbiMed Advisors's position in UNH was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's UNH position increasing or decreasing?
OrbiMed Advisors completely exited their UNH position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
UNHCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →